Treatment Patterns and Survival Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden – A Population-Based Register-Linkage and Medical Chart Review Study Abstract #1648

Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is a group of neoplasms derived from the endocrine system in the GI tract and pancreas.
Aim(s): To describe treatment patterns and survival among patients with metastatic GEP-NET grade 1 or 2 in Sweden.
Materials and methods: Patients diagnosed with metastatic GEP-NET grade 1 or 2 in 2005-2013 in Sweden were included (n=811; national population). Data was obtained via linkage of several nationwide registers. For the subpopulation diagnosed at Sahlgrenska University Hospital, Gothenburg (n=127; regional population), medical charts were reviewed. Treatment patterns and survival were assessed.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: PhD Åse Björstad

To read results and conclusion, please login ...

Further abstracts you may be interested in

#460 Treatment of Unresectable Metastatic GEP NETs: Data From a Prospective Observational Unicentric Study
Introduction: In 2010 Everolimus, Sunitinib and Capecitabine plus Temozolamide confirmed efficacy in NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Paula J Fonseca
#1303 Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals
Introduction: Lanreotide depot (LAN) was recently approved by the FDA to treat mGEP-NETs to improve progression-free survival.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: George Camba
Authors: Ortendahl J, Pulgar S, Cox D, Bentley T, ...
#1521 Metastatic Disease in Gastroenteropancreatic Neuroendocrine Cancer: Incidence, Treatment and Survival
Introduction: Data on patients with metastatic disease from GEP-NETs are rare.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Ariana Madani
#1563 Impact of Early Surgery on Prognosis in Advanced Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET)
Introduction: In gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) the role of surgery remains to be determined.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Patrizia Kump
#2104 Direct Cost of Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Relation to Time Since Diagnosis Shows Growing Importance of Somatostatin Analogues (SSA)
Introduction: Metastatic GEP-NET G1/G2 incurs large costs on the Swedish health care system.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PhD Daniel Granfeldt
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.